FibroGen Inc is a biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapies for anemia, fibrotic diseases, and chronic kidney disease
The organization focuses on the development of novel treatments that harness the body's natural processes to promote healthy red blood cell production and reduce fibrosis, thereby addressing significant unmet medical needs. Through its cutting-edge research and clinical trials, FibroGen aims to improve patient outcomes and enhance the quality of life for individuals suffering from these serious health conditions.
Given recent developments, several companies are anticipated to attract investor attention, making it an opportune moment to examine these events more closely. This feature will offer insights into five such companies.
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against FibroGen, Inc. (NASDAQFGEN) on behalf of long-term stockholders following a class action complaint that was filed against FibroGen on April 12, 2021 with a Class Period from December 20, 2018 to July 15, 2021. Our investigation concerns whether the board of directors of FibroGen have breached their fiduciary duties to the company.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of FibroGen, Inc. (“FibroGen” or “the Company”) (NASDAQFGEN) for violations of the securities laws.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of FibroGen, Inc. (“FibroGen” or “the Company”) (NASDAQFGEN) for violations of the securities laws.
SRPT stock fell 20% after the FDA changed course on their new DMD treatment approval. The stock remains strong with an encouraging outlook and a mod Buy rating.
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), provides an update to KSF’s continued investigation into FibroGen, Inc. (NasdaqGS: FGEN).
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), provides an update to KSF’s continued investigation into FibroGen, Inc. (NasdaqGS: FGEN).
San Diego, CA -- (SBWIRE) -- 06/24/2022 -- An investigation was announced for current long-term investors in shares of FibroGen, Inc. (NASDAQFGEN) over potential breaches of fiduciary duties by certain directors at FibroGen, Inc.
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into FibroGen, Inc. (NasdaqGS: FGEN).
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into FibroGen, Inc. (NasdaqGS: FGEN).
San Diego, CA -- (SBWIRE) -- 05/05/2022 -- An investor in FibroGen, Inc. (NASDAQFGEN) shares filed a lawsuit against certain directors of FibroGen, Inc over alleged breaches of fiduciary duties.
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into FibroGen, Inc. (NasdaqGS: FGEN).
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fibrogen, Inc. (NASDAQFGEN) on behalf of long-term stockholders following a class action complaint that was filed against Fibrogen on April 12, 2021. Our investigation concerns whether the board of directors of Fibrogen have breached their fiduciary duties to the company.
San Diego, CA -- (SBWIRE) -- 08/20/2021 -- An investigation on behalf of current long term investors in FibroGen, Inc. (NASDAQFGEN) shares over possible breaches of fiduciary duty by certain officers and directors was announced.
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of investors that purchased FibroGen, Inc. (NASDAQFGEN) securities and/or sold put options from October 18, 2017 and April 6, 2021, inclusive (the “Class Period”). Investors have until June 11, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed against FibroGen, Inc. (NASDAQFGEN) (“FibroGen”) on behalf of those who purchased or acquired FibroGen securities and/or sold put options from October 18, 2017 through April 6, 2021, inclusive (the “Class Period”).
The Law Offices of Frank R. Cruz reminds investors of the upcoming June 11, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired FibroGen Inc. (“FibroGen” or the “Company”) (NASDAQFGEN) securities between November 8, 2019 and April 6, 2021, inclusive (the “Class Period”).
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have only until June 11, 2021 to file lead plaintiff applications in securities class action lawsuits against FibroGen, Inc. (NasdaqGS: FGEN), if they purchased the Company’s securities and/or sold put options between October 18, 2017 and April 6, 2021, inclusive (the “Class Period”). These actions are pending in the United States District Court for the Northern District of California.
San Diego, CA -- (SBWIRE) -- 06/08/2021 -- A deadline is coming up on June 11, 2021 in the lawsuit filed for certain investors of FibroGen, Inc. (NASDAQFGEN).
